You are here

  • Home
  • Archive
  • Volume 15, Issue 4
  • Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone)

Article info

Article menu
Download PDFPDF
Therapeutics
Systematic review
Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone)

Authors

  1. Correspondence to Victor G Vogel
    American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA; victor.vogel{at}cancer.org
View Full Text

Citation

Vogel VG
Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone)
BMJ Evidence-Based Medicine 2010;15:122.

Publication history

  • First published August 3, 2010.
Online issue publication 
October 25, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions